CB2 Insights is now trading on the CSE under the symbol CBII
CB2 Insights focuses on standardized data collection of clinical trials protocols within medical cannabis industry, utilizing their own clinical asset combined with proprietary technology.
CEO Prad Sekar tells how the recent acquisition of Relax Clarity in Colorado expanded their base to over 80,000 patients across 14 states in the U.S., and how it could help filling the gap between crowd sourced anecdotal data and the lack of clinical trials within the medical cannabis space.
He believes this information could be utilized in future decision making support by stakeholders in a global medical cannabis industry.
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare.
We do so by gathering data and creating objective real-world evidence through our proprietary software and clinical service brands.
Using clinical management and data collection software at the point-of-care, CB2 Insights and its sub-brands have become a leading force bringing healthcare protocols to the rapidly evolving global cannabis industry.
CB2 Insights started trading on the Canadian Security Exchange under ticker symbol CBII.
For more information CB2 Insights Inc. (CBII:CSE) please fill out the form below.